Journals / Anadolu Kardiyoloji Dergisi / 2011 / Cilt: 11 - Sayı: 8

Diyabetik kardiyomiyopati

Diabetic cardiomyopathy

Pages
732–737
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, we aim to provide an extensive review on the pathophysiology, diagnosis, management of DCP. (Anadolu Kardiyol Derg 2011; 11: 732-7)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Diabetic individuals are at significantly greater risk of developing heart failure (HF) independent from other risk factors such as coronary artery disease (CAD) and hypertension.
📊
Key Findings & Data:Diabetic cardiomyopathy (DCP) is defined as ventricular dysfunction in the absence of hypertension, coronary artery and valvular heart disease, which increases the risk of HF.
💡
Conclusion & Impact:In this article, we aim to provide an extensive review on the pathophysiology, diagnosis, management of DCP. (Anadolu Kardiyol Derg 2011; 11: 732-7)
🔬Design:Review & Systematic Survey
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Diabetic individuals are at significantly greater risk of developing heart failure (HF) independent from other risk factors such as coronary artery disease (CAD) and hypertension. Diabetic cardiomyopathy (DCP) is defined as ventricular dysfunction in the absence of hypertension, coronary artery and valvular heart disease, which increases the risk of HF. Due to better understanding of its pathophysiology and clinical importance, DCP is more frequently recognized in daily practice. The most important mechanisms of DCP are hyperglycemia, insulin resistance/hyperinsulinemia, abnormal fatty acid metabolism, increased apoptosis, cardiac autonomic neuropathy and local renin-angiotensin-aldosterone system (RAAS) overactivation. Echocardiography is the most frequently used diagnostic method for the detection of this pathology. Currently, although there is no specific treatment for DCP, strict glycemic and concomitant risk factor controls seems to be the most important target strategy for prevention of the progression and treatment of DCP. In this article, we aim to provide an extensive review on the pathophysiology, diagnosis, management of DCP. (Anadolu Kardiyol Derg 2011; 11: 732-7)

Özet

Diyabetik bireyler koroner arter hastalığı, hipertansiyon gibi diğer faktörlerinden bağımsız olarak kalp yetersizliği gelişimi açısından artmış risk altındadırlar. Diyabetik kardiyomiyopati (DKP) hipertansiyon, koroner arter hastalığı ve kalp kapak hastalığı olmaksızın miyokart işlevinde bozulma şeklinde tanımlanmaktadır. Altta yatan patofizyolojik sürecin ve klinik öneminin daha iyi anlaşılmasıyla DKP günlük pratikte giderek daha fazla fark edilmektedir. Hiperglisemi, insülin direnci/hiperinsülinemi, bozulmuş yağ asidi metabolizması, artmış apoptozis, kardiyak otonomik nöropati ve lokal miyokardiyal renin-anjiyotensin sisteminin aşırı aktivasyonu altta yatan en önemli mekanizmalardır. DKP tanısında ekokardiyografi en sık kullanılan tanı metodudur. Günümüzde DKP’nin spesifik tedavisi olmasa da sıkı glisemik ve eşlik eden risk faktörleri kontrolü DKP’nin ilerlemesinin önlenmesinde ve tedavisinde en önemli hedef strateji gibi görünmektedir. Bu makalede DKP patofizyolojisi, tanısı ve tedavisi hakkında geniş bir derleme sunacağız. (Anadolu Kardiyol Derg 2011; 11: 732-7)

🔖

Cite This Article

Tayfun, Ş., YILMAZ, İ., URAL, D., ACAR, E., BİLDİRİCİ, D. (2022). Diyabetik kardiyomiyopati. Anadolu Kardiyoloji Dergisi, Cilt: 11 - Sayı: 8, 732–737. https://ajindex.com/articles/436759

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Silink M. Diabetes atlas foreword. International Diabetes Federation. 2009 August. Available from: URL: http://www.idf.org/ diabetesatlas/foreword
  2. Khavandi K, Khavandi A, Asghar O, Greenstein A, Withers S, Heagerty AM, et al. Diabetic cardiomyopathy- a distinct disease? Best Pract Res Clin Endocrinol Metab 2009; 23: 347-60
  3. Cohen-Solal A, Beauvais F, Loqeart D. Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J Card Fail 2008; 14: 615-25
  4. Murarka S, Movahed MR. Diabetic cardiomyopathy. J Card Fail 2010; 16: 971-9
  5. Bertoni AG, Tsai A, Kasper EK, Brancati FL. Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care 2003; 26: 2791-5
  6. Rubler S, Dlugash J, Yüceoğlu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595-602
  7. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115: 3213-23
  8. Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 2008; 121: 748-57
  9. Wynne J, Braunwald E. The cardiomyopathies. In: Zipes DP, Libby P, Bonow RO, Braunwald E, editors. Braunwald’s Heart Disease. 7th ed. PA: Saunders Elsevier; 2008. pp. 1659-96
  10. Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977; 60: 884-99
  11. Maya L, Villarreal FJ. Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis. J Mol Cell Cardiol 2010; 48: 524-9
  12. Wold LE, Relling DP, Colligan PB, Scott GI, Hintz KK, Ren BH, et al. Characterization of contractile function in diabetic hypertensive cardiomyopathy in adult rat ventricular myocytes. J Mol Cell Cardiol 2001; 33: 1719-26
  13. Bildirici U, Ural D, Acar E, Ağaçdiken A, Ural E. Diagnostic value of poor R-wave progression in electrocardiograms for diabetic cardiomyopathy in type 2 diabetic patients. Clin Cardiol 2010; 33: 559-64
  14. Szabo C. PARP as a drug target for the therapy of diabetic cardiovascular dysfunction. Drug News Perspect 2002; 15: 197-205
  15. Tarquini R, Lazzeri C, Pala L, Rotella CM, Gensini GF. The diabetic cardiomyopathy. Acta Diabetol 2011; 48: 173-81
  16. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengellér Z, Szabó C, et al. Inhibition of GAPDH activity by poly (ADP-ribose) polymerase activates